Alnylam Pharmaceuticals, Inc. (ALNY) presented KARDIA-2 Phase 2 study results of zilebesiran for the treatment of hypertension at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
The study met the primary endpoint showing that zilebesiran resulted in clinically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure (SBP) at Month 3 when Zilebesiran was added to a diuretic, calcium-channel blocker or angiotensin receptor blocker.
The company stated that the Zilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives and the study results support potential for biannual dosing of Zilebesiran.
Alnylam Pharma specified that full study results to be presented as a late-breaking clinical trial at the 2024 American College of Cardiology Annual Scientific Session on April 7.
Alnylam and Roche also announced the initiation of the KARDIA-3 Phase 2 study in adult patients with high cardiovascular risk and uncontrolled hypertension despite treatment with standard of care antihypertensive medications.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.